- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Arena Pharmaceuticals Gains on Clinical Trial Results
The Associated Press reported that Arena Pharmaceuticals Inc. (NASDAQ:ARNA) surged Wednesday after reporting positive results from an early clinical trial of a possible treatment for autoimmune diseases.
The Associated Press reported that Arena Pharmaceuticals Inc. (NASDAQ:ARNA) surged Wednesday after reporting positive results from an early clinical trial of a possible treatment for autoimmune diseases.
As quoted in the market news:
The San Diego company said its drug ADP334 reduced patients’ lymphocyte counts in an early-stage study of 50 healthy volunteers compared with a control group that received a placebo. Arena Pharmaceuticals said that measurement is linked to success in clinical studies of other treatments for multiple sclerosis, psoriasis, and ulcerative colitis.
Shares of Arena Pharmaceuticals Inc. gained $1.52, or 45.8 percent, to $4.84 in midday trading.
Click here to read the full report from The Associated Press.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â